小分子 CXCR2 和 CXCR1 拮抗剂抑制胰腺癌的肿瘤生长、血管生成和转移。
Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.
机构信息
Department of Pathology and Microbiology, 985950, Nebraska Medical Center, Omaha, NE, 68198-5900, United States.
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, 68198-5845, United States.
出版信息
Cancer Lett. 2023 Jun 1;563:216185. doi: 10.1016/j.canlet.2023.216185. Epub 2023 Apr 14.
Abstract
Pancreatic cancer (PC) has a poor prognosis, and current therapeutic strategies are ineffective in advanced diseases. We and others have shown the aberrant expression of CXCR2 and its ligands in PC development and progression. Our objective for this study was to evaluate the therapeutic utility of CXCR2/1 targeting using an small molecule antagonist, SCH-479833, in different PC preclinical murine models (syngeneic or xenogeneic). Our results demonstrate that CXCR2/1 antagonist had both antitumor and anti-metastatic effects in PC. CXCR2/1 antagonist treatment inhibited tumor cell proliferation, migration, angiogenesis, and recruitment of neutrophils, while it increased apoptosis. Treatment with the antagonist enhanced fibrosis, tumor necrosis, and extramedullary hematopoiesis. Together, these findings suggest that selectively targeting CXCR2/1 with small molecule inhibitors is a promising therapeutic approach for inhibiting PC growth, angiogenesis, and metastasis.
摘要
胰腺癌（PC）预后不良，目前的治疗策略在晚期疾病中无效。我们和其他人已经证明了 CXCR2 及其配体在 PC 发展和进展中的异常表达。我们这项研究的目的是评估使用小分子拮抗剂 SCH-479833 靶向 CXCR2/1 在不同 PC 临床前小鼠模型（同种异体或异种）中的治疗效果。我们的结果表明，CXCR2/1 拮抗剂在 PC 中具有抗肿瘤和抗转移作用。CXCR2/1 拮抗剂治疗抑制肿瘤细胞增殖、迁移、血管生成和中性粒细胞募集，同时增加细胞凋亡。拮抗剂治疗增强了纤维化、肿瘤坏死和骨髓外造血。总之，这些发现表明，用小分子抑制剂选择性靶向 CXCR2/1 是抑制 PC 生长、血管生成和转移的一种很有前途的治疗方法。
相似文献
1
Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer.小分子 CXCR2 和 CXCR1 拮抗剂抑制胰腺癌的肿瘤生长、血管生成和转移。
Cancer Lett. 2023 Jun 1;563:216185. doi: 10.1016/j.canlet.2023.216185. Epub 2023 Apr 14.
2
Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis.针对CXCR2和CXCR1的小分子拮抗剂通过降低肿瘤细胞增殖、存活及血管生成来抑制人黑色素瘤生长。
Clin Cancer Res. 2009 Apr 1;15(7):2380-6. doi: 10.1158/1078-0432.CCR-08-2387. Epub 2009 Mar 17.
3
A small-molecule antagonist of CXCR1 and CXCR2 inhibits cell proliferation, migration and invasion in melanoma via PI3K/AKT pathway.小分子 CXCR1 和 CXCR2 拮抗剂通过 PI3K/AKT 通路抑制黑色素瘤细胞增殖、迁移和侵袭。
Med Clin (Barc). 2019 Jun 7;152(11):425-430. doi: 10.1016/j.medcli.2018.08.006. Epub 2018 Oct 16.
4
The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.CXCR2 拮抗剂 SCH-527123 在临床前结肠癌模型中显示出抗肿瘤活性，并增强细胞对奥沙利铂的敏感性。
Mol Cancer Ther. 2012 Jun;11(6):1353-64. doi: 10.1158/1535-7163.MCT-11-0915. Epub 2012 Mar 5.
5
CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.使用CXCL8/白细胞介素-8类似物CXCL8(3 - 72)K11R/G31P对CXCR1/2进行拮抗，通过抑制肿瘤细胞增殖和抑制血管生成来限制肺癌生长。
Oncotarget. 2015 Aug 28;6(25):21315-27. doi: 10.18632/oncotarget.4066.
6
Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.癌细胞中表达的趋化因子达菲抗原受体（DARC）通过抑制人胰腺导管腺癌中的CXCR2信号传导来抑制肿瘤进展。
Cytokine. 2017 Jul;95:12-21. doi: 10.1016/j.cyto.2017.02.007. Epub 2017 Feb 20.
7
Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases.小分子 CXCR2 和 CXCR1 拮抗剂抑制人结肠癌肝转移。
Cancer Lett. 2011 Jan 28;300(2):180-8. doi: 10.1016/j.canlet.2010.10.004. Epub 2010 Oct 29.
8
Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.CXCL8受体CXCR1和CXCR2的功能活性对人类恶性黑色素瘤进展的影响
Eur J Cancer. 2009 Sep;45(14):2618-27. doi: 10.1016/j.ejca.2009.07.007. Epub 2009 Aug 13.
9
Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.小干扰 RNA 介导的 CXCR1 或 CXCR2 敲低抑制黑色素瘤肿瘤生长和侵袭。
Int J Cancer. 2010 Jan 15;126(2):328-36. doi: 10.1002/ijc.24714.
10
Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer.干扰素 γ 抑制 CXCL8-CXCR2 轴介导的肿瘤相关巨噬细胞肿瘤转移，并增强胰腺癌中抗 PD-1 的疗效。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000308.
引用本文的文献
1
Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity.肿瘤相关中性粒细胞的治疗潜力：双重作用与表型可塑性
Signal Transduct Target Ther. 2025 Jun 4;10(1):178. doi: 10.1038/s41392-025-02242-7.
2
Modulating the CXCR2 Signaling Axis Using Engineered Chemokine Fusion Proteins to Disrupt Myeloid Cell Infiltration in Pancreatic Cancer.利用工程化趋化因子融合蛋白调节CXCR2信号轴以破坏胰腺癌中的髓样细胞浸润
Biomolecules. 2025 Apr 30;15(5):645. doi: 10.3390/biom15050645.
3
The role of CXC chemokines and receptors in breast cancer.CXC趋化因子及其受体在乳腺癌中的作用。
Clin Exp Med. 2025 Apr 25;25(1):128. doi: 10.1007/s10238-025-01662-7.
4
Inhibition of Interleukin-8/C-X-C Chemokine Receptor 2 Signaling Axis Prevents Tumor Growth and Metastasis in Triple-Negative Breast Cancer Cells.抑制白细胞介素-8/C-X-C趋化因子受体2信号轴可预防三阴性乳腺癌细胞的肿瘤生长和转移。
Pharmacology. 2025 Apr 4:1-13. doi: 10.1159/000545659.
5
Macroautophagy/autophagy promotes resistance to KRAS-targeted therapy through glutathione synthesis.巨自噬/自噬通过谷胱甘肽合成促进 KRAS 靶向治疗的耐药性。
Cancer Lett. 2024 Nov 1;604:217258. doi: 10.1016/j.canlet.2024.217258. Epub 2024 Sep 12.
6
A key regulator of tumor-associated neutrophils: the CXCR2 chemokine receptor.肿瘤相关中性粒细胞的关键调节因子：CXCR2 趋化因子受体。
J Mol Histol. 2024 Dec;55(6):1051-1061. doi: 10.1007/s10735-024-10260-y. Epub 2024 Sep 13.
7
Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.靶向前列腺癌中的白细胞介素-8及其受体：炎症、应激反应与治疗抵抗
Cancers (Basel). 2024 Aug 8;16(16):2797. doi: 10.3390/cancers16162797.
8
A microphysiological system reveals neutrophil contact-dependent attenuation of pancreatic tumor progression by CXCR2 inhibition-based immunotherapy.微生理系统揭示了中性粒细胞通过 CXCR2 抑制为基础的免疫疗法的接触依赖性抑制胰腺肿瘤进展。
Sci Rep. 2024 Jun 19;14(1):14142. doi: 10.1038/s41598-024-64780-4.
9
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.揭示 CXCR2 作为肾细胞癌有希望的治疗靶点：通过 RCT001 抑制探索免疫治疗范式转变。
J Exp Clin Cancer Res. 2024 Mar 19;43(1):86. doi: 10.1186/s13046-024-02984-2.
10
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment.靶向免疫细胞的小分子：一种癌症治疗的新方法。
Biomedicines. 2023 Sep 24;11(10):2621. doi: 10.3390/biomedicines11102621.
本文引用的文献
1
Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers.CXCR2 的作用不断扩大及其在炎症性疾病和癌症中的治疗潜力。
Eur J Med Chem. 2023 Mar 15;250:115175. doi: 10.1016/j.ejmech.2023.115175. Epub 2023 Feb 7.
2
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer.靶向 T 细胞检查点 41BB 和 LAG3 以及髓样细胞 CXCR1/CXCR2 可引发抗肿瘤免疫并持久缓解胰腺癌。
Nat Cancer. 2023 Jan;4(1):62-80. doi: 10.1038/s43018-022-00500-z. Epub 2022 Dec 30.
4
CXCL8 in Tumor Biology and Its Implications for Clinical Translation.肿瘤生物学中的CXCL8及其临床转化意义
Front Mol Biosci. 2022 Mar 15;9:723846. doi: 10.3389/fmolb.2022.723846. eCollection 2022.
5
Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.胰腺导管腺癌（PDAC）循环肿瘤细胞影响髓样细胞分化，以支持其在门静脉循环中的存活和免疫抵抗。
PLoS One. 2022 Mar 22;17(3):e0265725. doi: 10.1371/journal.pone.0265725. eCollection 2022.
6
Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma.CXC受体2配体作为胰腺导管腺癌潜在生物标志物的差异表达谱
Am J Cancer Res. 2022 Jan 15;12(1):68-90. eCollection 2022.
7
Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity.趋化因子协调肿瘤细胞和微环境以实现转移异质性。
Cancer Metastasis Rev. 2021 Jun;40(2):447-476. doi: 10.1007/s10555-021-09970-6. Epub 2021 May 6.
8
Type I collagen deletion in αSMA myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer.Ⅰ型胶原在 αSMA 肌成纤维细胞中的缺失增强了免疫抑制作用，并加速了胰腺癌的进展。
Cancer Cell. 2021 Apr 12;39(4):548-565.e6. doi: 10.1016/j.ccell.2021.02.007. Epub 2021 Mar 4.
9
Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism.炎性细胞衍生的 CXCL3 通过一种新型的肌成纤维细胞劫持的癌症逃逸机制促进胰腺癌转移。
Gut. 2022 Jan;71(1):129-147. doi: 10.1136/gutjnl-2020-322744. Epub 2021 Feb 10.
10
Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis.宿主 Cxcr2 依赖性调控胰腺癌生长、血管生成和转移。
Am J Pathol. 2021 Apr;191(4):759-771. doi: 10.1016/j.ajpath.2021.01.002. Epub 2021 Jan 14.
Zotero 插件